“The existing circumstance has exposed some structural weaknesses from the EU’s medicines provide chain in addition to a substantial dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides said. She advisable that offer chain issues be tackled within an EU pharmaceutical tact